Division of Molecular Tumor Biology, Department of Molecular Biology, University of Salzburg, Salzburg, Austria.
Front Biosci (Landmark Ed). 2012 Jan 1;17(1):90-9. doi: 10.2741/3917.
It has been known for many years that cooperative interactions between oncogenes (e.g. RAS, MYC, BCL2) can fuel cancer growth (1-5), but the restricted druggability of many of those interacting cancer genes has hampered translation of combined targeting to medical cancer therapy. The identification and characterization of cooperative cancer signaling pathways amenable to medical therapy is therefore a crucial step towards the establishment of efficient targeted combination treatments urgently needed to improve cancer therapy. Here we review recent findings of our group and colleagues on the molecular mechanisms of cooperative Hedgehog/GLI and Epidermal Growth Factor Receptor (EGFR) signaling, two clinically relevant oncogenic pathways involved in the development of many human malignancies. We also discuss the possible implications of these findings for the design of a therapeutic regimen relying on combined targeting of key effectors of both pathways.
多年来,人们已经知道癌基因(例如 RAS、MYC、BCL2)之间的协同相互作用可以促进癌症的生长(1-5),但许多相互作用的致癌基因的药物开发受限,阻碍了联合靶向治疗在医学癌症治疗中的应用。因此,鉴定和描述可用于医学治疗的协同癌症信号通路是建立有效靶向联合治疗的关键步骤,这是迫切需要提高癌症治疗效果的关键步骤。在这里,我们回顾了我们小组和同事最近关于 Hedgehog/GLI 和表皮生长因子受体(EGFR)信号协同作用的分子机制的发现,这两个临床相关的致癌途径涉及许多人类恶性肿瘤的发生。我们还讨论了这些发现对设计依赖于两种途径的关键效应子联合靶向的治疗方案的可能影响。